Back
  1. Home
  2. Profile of Delphine Legrand (ULiège)
Profil

Legrand Delphine

See author's contact details
Main Referenced Co-authors
Scheen, André  (11)
Cavalier, Etienne  (4)
Delanaye, Pierre  (4)
Krzesinski, Jean-Marie  (4)
Radermecker, Régis  (4)
Main Referenced Keywords
Humans (10); Platelet Aggregation Inhibitors/therapeutic use (5); Aspirin/therapeutic use (4); Diabetes Mellitus, Type 1/drug therapy (2); Drug Resistance (2);
Main Referenced Disciplines
Endocrinology, metabolism & nutrition (11)
Laboratory medicine & medical technology (3)
Urology & nephrology (3)
Cardiovascular & respiratory systems (2)
Pharmacy, pharmacology & toxicology (2)

Publications (total 16)

The most downloaded
1843 downloads
Legrand, D., & Scheen, A. (2007). La consommation reguliere de cafe reduirait le risque de diabete de type 2. Revue Médicale de Liège, 62 (9), 554-9. https://hdl.handle.net/2268/4134

The most cited

28 citations (Scopus®)

Cavalier, E., Bekaert, A.-C., Carlisi, I., Legrand, D., Krzesinski, J.-M., & Delanaye, P. (2011). Neutrophil gelatinase-associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory's point of view. Clinical Chemistry and Laboratory Medicine, 49 (2), 339-341. doi:10.1515/CCLM.2011.044 https://hdl.handle.net/2268/79301

Gagneux-Brunon, A., DELANAYE, P., LEGRAND, D., CAVALIER, E., & Mariat, C. (December 2012). NGAL biomarqueur de lésion rénale. Néphrologie et Thérapeutique, 8 (7), 508-515. doi:10.1016/j.nephro.2012.03.006
Peer Reviewed verified by ORBi

Cavalier, E., Bekaert, A.-C., Carlisi, I., Legrand, D., Krzesinski, J.-M., & Delanaye, P. (2011). Neutrophil gelatinase-associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory's point of view. Clinical Chemistry and Laboratory Medicine, 49 (2), 339-341. doi:10.1515/CCLM.2011.044
Peer Reviewed verified by ORBi

Cavalier, E., Rozet, E., Bekaert, A.-C., Legrand, D., Krzesinski, J.-M., & Delanaye, P. (September 2010). Le dosage urinaire et plasmatique du NGAL: étude analytique et implications pratiques pour le clinicien. Néphrologie et Thérapeutique, 6 (5), 350.
Peer Reviewed verified by ORBi

Cavalier, E., Bekaert, A.-C., Legrand, D., Rozet, E., Krzesinski, J.-M., & Delanaye, P. (2010). Urinary NGAL: Use of absolute value or ratio to creatinine? Acta Clinica Belgica, 65-3, 13.
Peer Reviewed verified by ORBi

Legrand, D., Krzesinski, J.-M., & Scheen, A. (2008). Quelle place pour une double ou triple inhibition du systeme renine-angiotensine-aldosterone ? Revue Médicale Suisse, 4 (168), 1792-7.
Peer Reviewed verified by ORBi

Legrand, D., & Scheen, A. (2008). Cumul de facteurs de risque et interactions medicamenteuses aboutissant a une acidose lactique severe. Thérapie, 63 (1), 69-70. doi:10.2515/therapie:2008004
Peer Reviewed verified by ORBi

Legrand, D., & Scheen, A. (2007). La consommation reguliere de cafe reduirait le risque de diabete de type 2. Revue Médicale de Liège, 62 (9), 554-9.
Peer reviewed

Legrand, D., & Scheen, A. (2007). La resistance a l'aspirine chez le patient diabetique: decouverte de laboratoire ou realite clinique? Revue Médicale de Liège, 62 (10), 610-5.
Peer reviewed

Legrand, D., Radermecker, R., Stassen, M.-J., Soyeur, D., Radermecker, M., & Scheen, A. (2007). Staphylococcus aureus endocarditis in a diabetic woman treated by continuous subcutaneous insulin infusion. Diabetes and Metabolism, 33 (1), 79-81. doi:10.1016/j.diabet.2006.10.003
Peer Reviewed verified by ORBi

Scheen, A., & Legrand, D. (2007). Platelet dysfunction associated with insulin therapy in patients with type 2 diabetes: please do not throw the baby out with the bathwater! Journal of the American College of Cardiology, 49 (5), 628; author reply 628-9. doi:10.1016/j.jacc.2006.11.004
Peer Reviewed verified by ORBi

Legrand, D., & Scheen, A. (2006). L'aspirine en prevention primaire des maladies cardio-vasculaires chez le patient diabetique. Revue Médicale de Liège, 61 (10), 682-90.
Peer reviewed

Legrand, D., & Scheen, A. (2006). Prevention cardiovasculaire par l'aspirine chez le patient diabetique: que nous apprend la medecine factuelle? Revue Médicale Suisse, 2 (76), 1904-8.
Peer Reviewed verified by ORBi

Scheen, A., & Legrand, D. (2006). Aspirin and clopidogrel resistance in patients with diabetes mellitus. European Heart Journal, 27 (23), 2900; author reply 2900-1. doi:10.1093/eurheartj/ehl295
Peer Reviewed verified by ORBi

LEGRAND, D., SCHEEN, A., & RADERMECKER, R. (2006). L'insulinothérapie par pompe à perfusion continue d'insuline en pratique clinique: analyse rétrospective sur 508 patients-années. Diabète et Métabolisme, 32, 1S71.
Peer Reviewed verified by ORBi

LEGRAND, D., & RADERMECKER, R. (2005). L'insulinothérapie par pompe à perfusion sous cutanée d'insuline en pratique clinique: analyse rétrospective sur 508 patients-années. Infusystèmes France, 22 (4), 26-28.

Radermecker, R., Hermans, M. P., Legrand, D., & Scheen, A. (2005). L'insulinotherapie par pompe externe a perfusion continue d'insuline. Revue Médicale de Liège, 60 (5-6), 329-34.
Peer reviewed

Contact ORBi